Sponsors › University of Colorado Denver
University of Colorado Denver
Every GLP‑1 and incretin trial, approval and scheduled result we hold for University of Colorado Denver, drawn from ClinicalTrials.gov and Drugs@FDA.
University of Colorado Denver is an academic or hospital sponsor, not a drug company with 9 trials in the incretin class on file here, across 3 molecules. The programme is split between 2 early-stage trials and 7 in phase 3 or later. The next scheduled result is 2027-10-01.
- Molecules
- exenatide · semaglutide · tirzepatide
- Trials on file
- 9
- Active trials
- 5
- Results scheduled
- 0
- Approved FDA submissions
- 0
Trials on file
All 9 incretin trials recorded for this sponsor, active first.